0001437749-25-012093 Sample Contracts
EMPLOYMENT AGREEMENTEmployment Agreement • April 15th, 2025 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances) • Pennsylvania
This Employment Agreement (the “Agreement”) is made as of November 8, 2024, by and between Windtree Therapeutics, Inc., a Delaware corporation (the “Company”), and Jamie McAndrew (“Executive”), subject to the terms and conditions defined in this Agreement.
AMENDMENT NO. 1 TO THE LICENSE AGREEMENTLicense Agreement • April 15th, 2025 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances)
This Amendment No. 1 to the License Agreement (this “Amendment”), dated January 17, 2024 (the “Amendment Effective Date”), is made by and between Windtree Therapeutics, Inc., a Delaware corporation formerly known as Discovery Laboratories, Inc. (“Windtree”), and Philip Morris Products S.A., a Switzerland corporation (“PMPSA”). Windtree and PMPSA are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • April 15th, 2025 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances) • England and Wales
This License, Development and Commercialization Agreement (this “Agreement”) is entered into as of January 7, 2024 (the “Effective Date”), by and between Windtree Therapeutics, Inc., a Delaware corporation with its principal offices at 2600 Kelly Rd., Suite 100, Warrington, PA 18976 USA (“Licensor”), and Lee’s Pharmaceutical (HK) Ltd., a Hong Kong company organized and existing under the laws of Hong Kong with its principal offices at 1/F, Building 20E, Phase 3, Hong Kong Science Park, Shatin, Hong Kong (“Licensee”). Licensor and Licensee are sometimes referred to in this Agreement individually as a “Party” and together as the “Parties.”
AMENDMENT NO. 1 TO AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • April 15th, 2025 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances)
This Amendment No. 1 to Amended and Restated License Agreement (this “Amendment”), dated January 17, 2024 (the “Amendment Effective Date”), is made by and between Windtree Therapeutics, Inc., a Delaware corporation formerly known as Discovery Laboratories, Inc. (“Windtree”), and Philip Morris USA Inc., a Virginia corporation formerly referred to as Philip Morris USA Inc., d/b/a Chrysalis Technologies (“PM USA”). Windtree and PM USA are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
License and Supply AgreementLicense and Supply Agreement • April 15th, 2025 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances) • Delaware
This License and Supply Agreement (“Agreement”), dated and effective as of March __, 2025 (the “Effective Date”), is by and between Evofem Biosciences, Inc., a Delaware corporation, having its principal place of business at 12636 High Bluff Drive, Suite 400, San Diego, CA 92130 (“Buyer”) and Windtree Therapeutics, Inc., a Delaware corporation, having its principal place of business at 2600 Kelly Road, Suite 100, Warrington, PA 18976 (“Supplier”) (collectively, the “Parties,” or each, individually, a “Party”).
AMENDMENT NO. 1 TO LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • April 15th, 2025 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances) • California
This Amendment No. 1 to License and Supply Agreement dated as of March 20, 2025 (the “Amendment”), is by and between Evofem Biosciences, Inc., a Delaware corporation, having its principal place of business at 12636 High Bluff Drive, Suite 400, San Diego, CA 92130 (“Buyer”) and Windtree Therapeutics, Inc., a Delaware corporation, having its principal place of business at 2600 Kelly Road, Suite 100, Warrington, PA 18976 (“Supplier”) (collectively, the “Parties,” or each, individually, a “Party”), effective as of the date of last signature hereto (the “Amendment Effective Date”).